Manufacturing: Page 3
-
US stocks up on COVID-19 antibody drugs amid shortage concerns
Deals with Regeneron and Eli Lilly will secure nearly 1.8 million additional doses of the companies' respective treatments over the next four months.
By Ned Pagliarulo • Sept. 15, 2021 -
CureVac scales back mRNA manufacturing for coronavirus vaccine
The German biotech, which announced disappointing results for its shot in June, said the move was done in response to reduced demand.
By Shoshana Dubnow • Updated Sept. 15, 2021 -
Moderna expands mRNA vaccine supply in deal with new biotech producer
The company has previously said it could make up to 3 billion vaccine doses in 2022, depending on how booster shots are authorized.
By Shoshana Dubnow • Sept. 8, 2021 -
Eyeing future outbreaks, Moderna partners with Canadian government on vaccine plant
While Canada has already secured more COVID-19 vaccine doses than it needs, the factory to be built is geared toward combating future pandemics.
By Jonathan Gardner • Aug. 10, 2021 -
Amgen, expecting higher demand for its medicines, to build plant in North Carolina
The biotech is also constructing a new factory in Ohio and, between the two, expects to investment nearly $1 billion over the next few years.
By Kristin Jensen • Aug. 4, 2021 -
A pharma merger's impact ripples across West Virginia as Viatris plant closes
One of the country's oldest and largest drug manufacturing plants shut down Saturday, a consequence of the 2019 merger between Mylan and Pfizer's Upjohn unit. The impact will be felt by a West Virginia city for years to come.
By Shoshana Dubnow • July 30, 2021 -
Bluebird preps for split by selling manufacturing plant to well-funded startup
The startup manufacturing specialist National Resilience, which raised $800 million when it launched last year, will pay Bluebird $110 million for the North Carolina facility, bringing its North American network up to 10.
By Kristin Jensen • July 29, 2021 -
BioNTech, WHO hatch plan to bring mRNA vaccines to Africa
Responding to criticism, the German biotech plans to develop a malaria shot and build manufacturing infrastructure on the continent.
By Jonathan Gardner • July 26, 2021 -
Sponsored by ZS
Trends shaping biopharma's role in the healthcare ecosystem
Four trends are shaping the healthcare ecosystem. These present new opportunities for biopharma.
By Pratap Khedkar and Jude Konzelmann • July 26, 2021 -
Sponsored by Avid Bioservices
Unique commercial experience primes Avid Bioservices for growth
Discover the bioservices and manufacturing efforts that have made an impact within the biological manufacturing field.
By Nick Green, Chief Executive Officer, Avid Bioservices • June 28, 2021 -
Sponsored by Emergent Biosolutions
Lyophilized products are on the rise: Here's what you need to know
To extend the shelf life and improve stability of biopharmaceuticals, a freeze-drying process—and a partner—can help.
By Kate Silver • June 14, 2021 -
UK drug contractor to be sold to private equity firm in $1.4B deal
Through a subsidiary, The Carlyle Group will pay a 27% premium to acquire Vectura, a CDMO that specializes in inhaled medicines.
By Kristin Jensen • May 26, 2021 -
Emergent CEO defends company from criticism of error that ruined vaccine doses
The company expects to respond within days to a long list of findings FDA officials made in an inspection of Emergent's Baltimore plant earlier this month.
By Ned Pagliarulo • April 30, 2021 -
Moderna plans to triple coronavirus vaccine production next year
The biotech aims to double capacity at plants in Switzerland and Spain, and by 50% at U.S. sites. The total number, however, will depend on the mix of primary and booster doses.
By Jonathan Gardner • April 29, 2021 -
Gilead, Merck to help India access COVID-19 drugs as country's crisis deepens
Gilead will donate at least 450,000 vials of Veklury, while Merck licensed its experimental antiviral molnupiravir to five generic drugmakers in India.
By Ned Pagliarulo • April 27, 2021 -
Sanofi to aid Moderna on final steps in manufacturing coronavirus vaccine
The French pharma has agreed to "fill and finish" up to 200 million vials of Moderna's shot at its New Jersey plant, the third such manufacturing deal it struck with other vaccine developers.
By Ned Pagliarulo • April 26, 2021 -
FDA cites Emergent for failings at plant that contaminated J&J doses
A recent nine-day inspection by agency officials found numerous breaches of manufacturing standards and inadequate training for factory employees.
By Ned Pagliarulo • April 22, 2021 -
J&J to oversee vaccine production at Emergent factory that ruined doses
The change, which follows the contractor's costly manufacturing mix-up, will displace production of AstraZeneca's unauthorized shot at the Baltimore site.
By Ned Pagliarulo • April 5, 2021 -
Manufacturing mix-up could blunt supply boost from J&J vaccine
One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses.
By Ned Pagliarulo • April 1, 2021 -
Sponsored by Reed Tech
How to navigate Health Canada XML PM requirements
Learn the latest about XML PM mandates and timelines from structured labeling experts.
March 22, 2021 -
Sponsored by Millipore-Sigma®
Paving the way towards the biomanufacturing facility of the future
Technologies that enable bioprocessing 4.0 are creating the roadmap to the facility of the future.
By Merrilee Whitney, Head of the BioContinuum™ platform • March 15, 2021 -
Vaccine factories churn out millions more doses, speeding US rollout of coronavirus shots
The U.S. is now averaging more than 2 million doses given each day, a pace that will help President Joe Biden meet his target of 100 million shots in 100 days well ahead of schedule.
By Ned Pagliarulo • March 11, 2021 -
Merck to help J&J make vaccine doses in White House-brokered deal
The U.S. government will give Merck $269 million to help the drugmaker retool two of its facilities to make J&J's one-dose shot.
By Jonathan Gardner • Updated March 2, 2021 -
Moderna, Pfizer ready multi-pronged plans for coronavirus variants
Moderna has delivered a modified version of its vaccine to NIH scientists, while Pfizer has begun testing of an additional booster shot in a clinical trial, both precautionary steps against emerging strains.
By Jonathan Gardner , Ben Fidler • Updated Feb. 25, 2021 -
Pfizer set to double weekly production of coronavirus vaccine
The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday.
By Ned Pagliarulo • Feb. 19, 2021